Epilepsy associated with lupus anticoagulant  by Gibbs III, John W. & Husain, Aatif M.
doi:10.1053/seiz.2001.0578, available online at http://www.idealibrary.com on
Seizure 2002; 11: 207–209
Epilepsy associated with lupus anticoagulant∗
JOHN W. GIBBS III† & AATIF M. HUSAIN‡
†Department of Medicine (Neurology), Duke University, Durham, NC, USA; ‡Neurodiagnostic
Center, Veterans Affairs Medical Center, Durham, NC, USA
Correspondence to: Aatif M. Husain, MD, Department of Medicine (Neurology), 202 Bell Building, Box 3678, Duke
University Medical Center, Durham, NC 27710, USA. E-mail: aatif.husain@duke.edu
Introduction: Lupus anticoagulant (LA) is commonly present in patients with systemic lupus erythematosus (SLE) who present
with an ischemic cerebral stroke. Reports have noted the presence of LA in patients with epilepsy who do not have SLE. These
patients are usually elderly, and it has been postulated that their epilepsy is due to subclinical ischemic infarcts.
Methods: Two cases are presented in young patients (age < 35 years) who developed epileptic seizures and were LA positive.
These patients did not have SLE or have cerebral infarcts that could explain the presence of their seizures.
Results: A 28-year-old woman was admitted for aortic insufficiency and new onset seizures. The clinical history, physical
examination and magnetic resonance imaging did not reveal an antecedent cortical ischemic event. Serological testing revealed
the presence of LA. The second patient was a 33-year-old man with medically intractable epilepsy in whom serological testing
revealed the presence of LA. The clinical history, physical examination, and MRI did not reveal any evidence of an antecedent
ischemic event. Neither patient had SLE.
Conclusions: In young patients without SLE and cerebral infarcts, LA may be associated with epileptic seizures.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Lupus anticoagulant (LA) and anticardiolipin antibod-
ies (ACA) are antiphospholipid antibodies (APLA).
APLA are associated with thrombosis, fetal loss
and thrombocytopenia in systemic lupus erythe-
matosus (SLE). There are anecdotal reports of the
association of APLA in patients with myelopathy,
Guillain–Barre´ syndrome, migraine, chorea, optic
neuritis, myasthenia gravis and epileptic seizures1.
The recognition of these immunoglobulin fractions in
association with neurological diseases could impact
the manner in which each individual syndrome is
treated.
APLA occur in high prevalence in patients with
SLE. Currently, the pathogenesis of epilepsy in SLE
is unclear. Seizures can occur as a result of ischemic
vascular infarcts; however, it is possible that antibody
fractions bind to the cerebral cortex by an immune-
mediated mechanism which predisposes the patient to
develop seizures. In the past, studies have attempted
to correlate the presence of APLA fractions and
an increased incidence of epileptic seizures2, 3. This
paper describes two young patients with epilepsy who
did not fulfill the criteria for SLE who were found to
have LA present in their sera.
CASE REPORTS
Case 1
A 28-year-old, right-handed woman with no signif-
icant past medical history presented with her first
seizure. Two days prior to presentation she had a sud-
den onset of a severe occipital headache and blurred
vision. These symptoms resolved spontaneously after
ten minutes. Later that evening she had a generalized
tonic–clonic seizure that lasted about 2 minutes. In the
emergency department she denied recent fever, chills,
nausea or vomiting. There was no history of abuse
of alcohol, drugs or tobacco. She was not taking any
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medications. Her past medical history was significant
for sickle cell trait, a cholecystectomy several years
previously and two miscarriages. Her family history
was significant for a mother who had SLE and several
cousins with seizures. A rheumatological consultant
noted that she did not have the clinical features of
SLE. Physical examination was significant for an
II/VI diastolic cardiac ejection murmur. Her neu-
rological examination was normal. Serological tests
revealed a prolonged activated partial thromboplastin
time (aPTT) of 48 seconds and LA was positive.
An electroencephalogram (EEG) revealed recurrent
left temporal spike discharges. Magnetic resonance
imaging (MRI) and MR angiography (MRA) of the
brain showed an area of hyperintensity in the left
posterior parietal and periventricular white matter. No
cortical lesions or other abnormalities were noted.
Case 2
A 34-year-old man presented for evaluation of medi-
cally refractory seizures. He denied the use of alcohol,
drugs, or tobacco. His past medical history was
significant for a motor vehicle accident 10 years prior
to his seizure onset, subsequent partial paraparesis
and bilateral deep vein thromboses. Medications on
presentation were carbamazepine and warfarin. His
family history was noncontributory. General physical
and neurological examinations were remarkable for
bilateral lower extremity atrophy and weakness (4/5).
His serological tests revealed a prolonged aPTT of
48 seconds and LA was positive. An EEG revealed
bitemporal sharp waves whereas a brain MRI showed
two small areas of hyperintensity in the left deep
frontal white matter.
DISCUSSION
Two young patients with epileptic seizures who
were LA positive and did not have SLE or cerebral
cortical infarcts are presented. Previous case reports
of epilepsy and LA without SLE have been of
older patients (50–75 years old) with some showing
brain atrophy or gray matter cerebral infarction. In
this paper LA-positive patients with seizures were
significantly younger and only had minimal white
matter abnormalities. This suggested an etiology inde-
pendent of arterial infarction associated with strokes
as the causative mechanism for epilepsy in these
cases. Therefore, the presence of LA in young adults
without SLE may be associated with an increased
susceptibility to develop epileptic seizures by a yet
poorly understood antibody-mediated immunologic
mechanism.
Approximately 10% of all patients with SLE
develop epileptic seizures at some stage of their
disease2, which is almost ten times greater than that
of the general population. Between 5–10% of those
patients have onset of seizures several years before
clinical onset of SLE4. For years it was thought that
seizures in SLE were a result of thrombosis of cortical
blood vessels induced by the procoagulant effects
of APLA. The resulting cortical infarction would be
more prone to pathological epileptic activity5.
LA, an APLA fraction, despite inducing a pro-
thrombotic state, prolongs coagulation by interact-
ing with phospholipid-dependent mechanisms. LA
inhibits prothrombinase (a complex of factors Xa,
Va, phospholipid, and calcium), thereby blocking the
activation of prothrombin by the complex. Paradoxi-
cally, the characteristic serological abnormalities are a
prolonged aPTT and PT even though a procoagulant
state is present in the serum6. The precise mechanism
by which LA induces a prothrombotic state is poorly
understood, but presumed mechanisms include dys-
function of endothelial cells, platelets, and coagulation
proteins7, 8.
In the present cases, it was initially believed that
seizures were due to a vascular insult in the gray
matter that made the tissue epileptogenic. However,
the neurological examination and neuroimaging did
not suggest cortical involvement in either case. Also,
these patients did not fulfill the American Rheumatism
Association criteria for SLE9. This suggested other
neuropathological mechanisms might be responsible
for the etiology of the seizures in these patients.
Immune system mechanisms play an important
role in some forms of epilepsy. In patients with
Rasmussen’s encephalitis (RE), a particularly severe
form of epilepsy, patients gradually develop refractory
continuous partial seizures or epilepsia partialis
continua through an immune complement mechanism
mediated by glutamate receptor 3 (GluR3) autoanti-
bodies to cortical neurons10, 11. Removal of antibodies
through plasma exchange has been demonstrated to
reduce the seizure frequency and improve neurologic
function transiently10. Similarly, it has been suggested
that epilepsy in patients with SLE may be a
secondary result of an immune-mediated mechanism
by APLA, independent of thrombotic infarcts as
has been previously hypothesized2, 3. Chapman et al.
12 demonstrated that IgG from patients with high
levels of APLA depolarized synaptosomes from
rodent brainstem. The depolarization of neurons by
APLA could theoretically lower the seizure threshold,
thereby predisposing the tissue to epileptogenesis.
While the present case series included only two
patients who were LA positive without SLE and had
seizures, previous clinical reports have noted an asso-
ciation between the presence of APLA and increased
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epileptic seizure prevalence. Inzelberg and Korczyn3
described four patients with late-onset seizures (age
> 54 years old) who had LA-positive sera but not
clinical SLE and minimal brain MRI changes. Other
retrospective case reports have correlated an increased
seizure frequency in patients with SLE who also had
APLA in their sera. In 21 unselected patients with
seizures of unclear etiology, epilepsy was statistically
significantly associated with the presence of ACA
and/or LA fractions in comparison to controls2. In
another study of patients with SLE, epilepsy was
3.7 times more frequent in patients who had ACA
than in those who did not have ACA13. In a series
of 23 children with cryptogenic epileptic seizures
without serological evidence of SLE or MRI evidence
of focal ischemic infarcts, three had frontal lobe
seizures and APLA present in their sera14.
Currently, there are few data to suggest that
immune-mediated mechanisms are intimately in-
volved in the pathophysiology of any epilepsy other
than RE. However, case reports suggest that the
presence of ACLA, like LA, may make a patient more
susceptible to the future development or exacerbation
of underlying epileptic seizures. This, in turn, may
create alternative therapies for patients with these
types of seizures.
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